Oral amoxicillin — Competitive Intelligence Brief

Oral amoxicillin (Oral amoxicillin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (aminopenicillin). Area: Infectious Disease.

marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan Infectious Disease Small molecule

Target snapshot

Oral amoxicillin (Oral amoxicillin) — Boston Medical Center. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral amoxicillin TARGET	Oral amoxicillin	Boston Medical Center	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Amoxicillin Short	Amoxicillin Short	Universita degli Studi di Genova	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
P.O moxypen 500 mgx3/d for 5 days	P.O moxypen 500 mgx3/d for 5 days	Western Galilee Hospital-Nahariya	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Ampicillin for Injection	Ampicillin for Injection	Medical College of Wisconsin	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Amoxicillin Capsules	Amoxicillin Capsules	The Third Xiangya Hospital of Central South University	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Quick response: Amoxicillin for 5 days	Quick response: Amoxicillin for 5 days	University Hospital, Montpellier	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Ampicillin Injection	Ampicillin Injection	Far Eastern Memorial Hospital	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (aminopenicillin) class)

1. University Hospital, Montpellier · 2 drugs in this class
2. Western Galilee Hospital-Nahariya · 2 drugs in this class
3. Medical College of Wisconsin · 1 drug in this class
4. Norwegian University of Science and Technology · 1 drug in this class
5. Boston Medical Center · 1 drug in this class
6. The Third Xiangya Hospital of Central South University · 1 drug in this class
7. Universita degli Studi di Genova · 1 drug in this class
8. Rabin Medical Center · 1 drug in this class
9. Far Eastern Memorial Hospital · 1 drug in this class